Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.93 (market cap $1.74B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.78 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 96.8× Nuvation Bio Inc. Class A Common Stock's market cap, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Vanguard Emerging Markets Stock Index Fund ETF for 134 Days on average.
| NUVB | VWO | |
|---|---|---|
Market Cap | $1.74B | $168.50B |
Volume | 9,289,619 | 9,650,999 |
Sector | Health | — |
52-Week High | $9.54 | $61.44 |
52-Week Low | $3.41 | $52.42 |
Typical Hold Time | 0 Days | 134 Days |
Enterprise Value | $1.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VWO trades at $59.85, down 1.27% with a bearish technical signal. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic weakness creates headwinds. Institutional ownership has increased with Allianz Asset Management growing its stake by 12.6% in Q3 2026, though technical indicators show selling pressure outweighing buying signals.
The outlook remains cautious with emerging markets facing economic divergence. Opportunities exist in semiconductor and technology exposure, but risks include China's property slump and currency volatility. Wall Street sentiment is neutral with the ETF trading near key support levels amid global market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
